Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 730 (ZNF730)
- Target
- ZNF730
- Molecular classification
- Transcription factor, C2H2-type zinc finger protein, Kruppel-associated box (KRAB) domain-containing protein
01
Overview
Zinc finger protein 730 is a nuclear, DNA-binding transcription factor belonging to the C2H2-type zinc finger protein family, the largest class of transcription factors in humans. The protein contains 12 C2H2 zinc finger motifs and one KRAB domain, functioning in transcriptional regulation by binding specific DNA sequences and potentially interacting with other proteins and RNA. ZNF730 is highly expressed in the testis, brain, lymph nodes, and placenta, and is implicated in processes such as gametogenesis and central nervous system development. Mutations or altered expression of ZNF730 have been found in a subset of endometrial and breast cancers, suggesting potential oncogenic roles. Although ZNF730 is not currently considered a direct therapeutic target, its regulatory functions and roles in cancer biology continue to be explored.
- Other names
- ZNF730zinc finger protein 730NCBI Gene ID: 100129543HGNC: 32470UniProt: Q6ZMV8Ensembl: ENSG00000183850
02
Mechanism of action
Not applicable—no direct targeting drugs or mechanisms have been described for ZNF730
03
Biological functions
Transcriptional regulationDNA binding as a transcription factorPossible regulation of gene expression in cell development and differentiationMay participate in post-translational modification processes such as phosphorylation and SUMOylation
04
Disease associations
Cancer, especially endometrial cancer and acute myeloid leukemia (expression/mutations reported)Possible roles in breast cancer, based on mutation dataOther cancer-related processes via transcription regulation
05
Safety considerations
None specifically documented for ZNF730 as a therapeutic target. Because it is not targeted by drugs, no direct safety concerns are described
06
Biomarkers
Not currently used as a clinical biomarker, but higher expression of ZNF730 has been observed in cancerous tissues (endometrial cancer, acute myeloid leukemia, possibly in breast cancer)
Beyond the preview
Go deeper on Zinc finger protein 730 (ZNF730).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 730 (ZNF730).